# A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i

> **NCT05953350** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 29 (estimated)

## Conditions studied

- Inhibition of Autophagy Synergizes Anti-tumor Effect

## Interventions

- **DRUG:** 600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
- **DRUG:** RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.

## Key facts

- **NCT ID:** NCT05953350
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-07
- **Primary completion:** 2024-05-07
- **Final completion:** 2024-12-31
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05953350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05953350, "A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05953350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*